Table 4.

Summary of adverse events during 36-week open-label phase

	Entecavir 1 mg (n = 145)
Any adverse event (%)a	79 (54)
Most frequent adverse events (%)
Upper respiratory tract infection	17 (12)
Fatigue	10 (7)
Hepatic pain	10 (7)
Serious adverse event (%)	2 (1)
Discontinuation due to adverse event (%)	0 (0)
Death	1 (<1)b

^aIncluding laboratory abnormalities reported by investigator as an adverse event.

^bConsidered unrelated to study medication by investigator